iShares Biotechnology ETF $IBB is Rye Brook Capital LLC’s 10th Largest Position

Rye Brook Capital LLC raised its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 13.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,300 shares of the financial services provider’s stock after buying an additional 2,800 shares during the quarter. iShares Biotechnology ETF comprises about 3.2% of Rye Brook Capital LLC’s investment portfolio, making the stock its 10th largest holding. Rye Brook Capital LLC owned approximately 0.06% of iShares Biotechnology ETF worth $3,074,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Signet Financial Management LLC grew its stake in shares of iShares Biotechnology ETF by 3.3% during the 2nd quarter. Signet Financial Management LLC now owns 2,579 shares of the financial services provider’s stock worth $326,000 after purchasing an additional 83 shares during the period. Apollon Wealth Management LLC grew its stake in shares of iShares Biotechnology ETF by 1.1% during the 1st quarter. Apollon Wealth Management LLC now owns 8,754 shares of the financial services provider’s stock worth $1,120,000 after purchasing an additional 96 shares during the period. SBI Securities Co. Ltd. grew its stake in shares of iShares Biotechnology ETF by 5.2% during the 1st quarter. SBI Securities Co. Ltd. now owns 2,198 shares of the financial services provider’s stock worth $281,000 after purchasing an additional 108 shares during the period. Wealthcare Advisory Partners LLC grew its stake in iShares Biotechnology ETF by 1.1% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 10,651 shares of the financial services provider’s stock valued at $1,362,000 after acquiring an additional 111 shares during the period. Finally, KFG Wealth Management LLC grew its stake in iShares Biotechnology ETF by 4.8% in the 2nd quarter. KFG Wealth Management LLC now owns 2,444 shares of the financial services provider’s stock valued at $309,000 after acquiring an additional 112 shares during the period. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Price Performance

iShares Biotechnology ETF stock opened at $151.99 on Thursday. The company’s fifty day moving average price is $140.21 and its 200 day moving average price is $130.36. iShares Biotechnology ETF has a 1 year low of $107.43 and a 1 year high of $153.01.

iShares Biotechnology ETF Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 19th. Investors of record on Tuesday, September 16th were paid a $0.0828 dividend. The ex-dividend date of this dividend was Tuesday, September 16th. This represents a $0.33 dividend on an annualized basis and a yield of 0.2%.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.